Skip to main content Accessibility help
×
Home

Effects of erythropoietin on body composition and fat–glucose metabolism in patients with affective disorders

  • Maj Vinberg (a1), Pernille Højman (a2), Bente Klarlund Pedersen (a2), Lars Vedel Kessing (a1) and Kamilla W. Miskowiak (a1) (a3)...

Abstract

Background

Erythropoietin (EPO) has been suggested to improve metabolism and also cognition, but human studies are scarce. This randomised controlled trial aimed to investigate whether EPO treatment influences body composition and fat and glycated haemoglobin (HbA1c) and fasting glucose, and whether these changes would be associated with previous observed cognitive benefits of EPO.

Method

In total, 84 non-obese patients with treatment-resistant unipolar depression or bipolar disorder in remission were randomised to 8 weekly EPO (40,000 IU) or saline (NaCl 0.9%) infusions in a double-blind, parallel-group design. Patients underwent dual X-ray absorptiometry scans at baseline and week 14 (6 weeks after treatment completion). Cognitive measures were assessed and fasting levels of cholesterol, lipoprotein fractions, triacylglycerides, glucose and HbA1c were obtained at baseline, week 9 and follow-up week 14.

Results

In total, 79 patients had complete pre- and post-treatment data (EPO: N=40, saline: N=39). EPO had no cumulative effect on body composition and markers of fat metabolism. The EPO-treated group exhibited significantly lower HbA1c levels after 8 weeks treatment [F(1, 80)=8.51, p=0.005], however, 6 weeks after treatment termination a significantly higher fasting glucose levels [F(1, 79)=5.85, p=0.02] and HbA1c levels [F(1, 79)=5.85, p=0.02] were seen. The latter increase in HbA1c was further significantly correlated with a better cognitive outcome on verbal memory (r=0.25, p=0.03).

Conclusion

Repeated EPO infusions had no cumulative effect on body composition in this cohort of patients with affective disorders, however, EPO modulated HbA1c and fasting glucose and this was associated with patients’ improvement of verbal memory.

Copyright

Corresponding author

Author for correspondence: Maj Vinberg, Psychiatric Centre Copenhagen, Rigshospitalet, University Hospital of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. Tel: +45 3864 7026; Fax: +45 3864 7022; E-mail: maj.vinberg@regionh.dk

References

Hide All
1. Maiese, K (2016) Regeneration in the nervous system with erythropoietin. Front Biosci (Landmark Ed) 21, 561596.
2. Ma, C, Cheng, F, Wang, X, Zhai, C, Yue, W, Lian, Y Wang, Q (2016) Erythropoietin pathway: a potential target for the treatment of depression. Int J Mol Sci 17, 124.
3. Recny, MA, Scoble, HA Kim, Y (1987) Structural characterization of natural human urinary and recombinant DNA-derived erythropoietin. Identification of des-arginine 166 erythropoietin. J Biol Chem 262, 1715617163.
4. Sytkowski, AJ (2011) The neurobiology of erythropoietin. Cell Mol Neurobiol 31, 931937.
5. Lappin, TR, Maxwell, AP Johnston, PG (2002) EPO’s alter ego: erythropoietin has multiple actions. Stem Cells 20, 485492.
6. Chong, ZZ, Shang, YC, Mu, Y, Cui, S, Yao, Q Maiese, K (2013) Targeting erythropoietin for chronic neurodegenerative diseases. Expert Opin Ther Targets 17, 707720.
7. Miskowiak, KW (2017) Could EPO studies improve mood disorder treatment strategies? Expert Rev Neurother 17, 9799.
8. Katz, O, Stuible, M, Golishevski, N, Lifshitz, L, Tremblay, ML, Gassmann, M, Mittelman, M Neumann, P (2010) Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models. J Endocrinol 205, 8795.
9. Hojman, P, Taudorf, S, Lundby, C Pedersen, BK (2009) Erythropoietin augments the cytokine response to acute endotoxin-induced inflammation in humans. Cytokine 45, 154157.
10. Maiese, K (2015) Erythropoietin and diabetes mellitus. World J Diabetes 6, 12591273.
11. McCrimmon, RJ, Ryan, CM Frier, BM (2012) Diabetes and cognitive dysfunction. Lancet 379, 22912299.
12. Mansur, RB, Cha, DS, Woldeyohannes, HO, Soczynska, JK, Zugman, A, Brietzke, E McIntyre, RS (2014) Diabetes mellitus and disturbances in brain connectivity: a bidirectional relationship? Neuromolecular Med 16, 658668.
13. Laursen, TM, Wahlbeck, K, Hallgren, J, Westman, J, Osby, U, Alinaghizadeh, H, Gissler, M Nordentoft, M (2013) Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries. PLoS One 8, e67133.
14. Garcia-Rizo, C, Kirkpatrick, B, Fernandez-Egea, E, Oliveira, C Bernardo, M (2016) Abnormal glycemic homeostasis at the onset of serious mental illnesses: a common pathway. Psychoneuroendocrinology 67, 7075.
15. Miskowiak, KW, Rush, AJ Jr., Gerds, TA, Vinberg, M Kessing, LV (2016) Targeting treatments to improve cognitive function in mood disorder: suggestions from trials using erythropoietin. J Clin Psychiatry 77, e1639e1646.
16. Miskowiak, KW, Vinberg, M, Harmer, CJ, Ehrenreich, H, Knudsen, GM, Macoveanu, J, Hansen, AR, Paulson, OB, Siebner, HR Kessing, LV (2010) Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder. Trials 11, 97.
17. Miskowiak, KW, Vinberg, M, Christensen, EM, Bukh, JD, Harmer, CJ, Ehrenreich, H Kessing, LV (2014) Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial. Neuropsychopharmacology 39, 13991408.
18. Miskowiak, KW, Ehrenreich, H, Christensen, EM, Kessing, LV Vinberg, M (2014) Recombinant human erythropoietin to target cognitive dysfunction in bipolar disorder: a double-blind, randomized, placebo-controlled phase 2 trial. J Clin Psychiatry 75, 13471355.
19. Posternak, MA, Young, D, Sheeran, T, Chelminski, I, Franklin, CL Zimmerman, M (2004) Assessing past treatment history: test-retest reliability of the treatment response to antidepressant questionnaire. J Nerv Ment Dis 192, 95102.
20. Hamilton, M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6, 278296.
21. Young, RC, Biggs, JT, Ziegler, VE Meyer, DA (1978) A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133, 429435.
22. Fava, M, Iosifescu, DV, Pedrelli, P Baer, L (2009) Reliability and validity of the Massachusetts general hospital cognitive and physical functioning questionnaire. Psychother Psychosom 78, 9197.
23. Schmidt, RA (1971) Retroactive interference and amount of original learning in verbal and motor tasks. Res Q 42, 314326.
24. Randolph, C, Tierney, MC, Mohr, E Chase, TN (1998) The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 20, 310319.
25. Ryan, JJ, Sattler, JM Lopez, SJ (2000) Age effects on Wechsler Adult Intelligence Scale-III subtests. Arch Clin Neuropsychol 15, 311317.
26. Reitan, RM (1955) The relation of the trail making test to organic brain damage. J Consult Psychol 19, 393394.
27. Shapiro, R, McManus, MJ, Zalut, C Bunn, HF (1980) Sites of nonenzymatic glycosylation of human hemoglobin A. J Biol Chem 255, 31203127.
28. De Melo, LGP, Nunes, SOV, Anderson, G, Vargas, HO, Barbosa, DS, Galecki, P, Carvalho, AF Maes, M (2017) Shared metabolic and immune-inflammatory, oxidative and nitrosative stress pathways in the metabolic syndrome and mood disorders. Prog Neuropsychopharmacol Biol Psychiatry 78, 3450.

Keywords

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed